In a significant development regarding warnings about side effects associated with Depo-Provera injections, an FDA-ordered change to the Depo-Provera drug label added a meningioma warning in December 2025. Put differently, before this Depo-Provera label change, there was no meningioma warning in any of the previous Depo-Provera drug labels, also known as the Prescribing Information documents.
As you may have heard, Depo-Provera meningioma drug injury lawsuits have been filed against the responsible pharmaceutical drug companies in the past year or two.
This Depo-Provera label change has some people asking whether new Depo-Provera lawsuits can be filed in 2026, after this new meningioma warning was added to the Depo-Provera drug label.
We want to reassure women diagnosed with meningioma that they can file a new Depo-Provera lawsuit in 2026 if they were receiving Depo-Provera injections before this Depo-Provera label change in December 2025 that added the meningioma warning.
The reason a considerable number of Depo-Provera meningioma drug injury lawsuits will likely be filed in 2026 and the couple of years thereafter is that there is a delay, or “latency period”, from the time when a woman has Depo-Provera injections until that woman is diagnosed with meningioma.
Depo-Provera Lawsuits After This December 2025 Depo-Provera Label Change Added Meningioma
Women need to know that (a) if they used Depo-Provera before December 2025, and (b) they received a meningioma diagnosis before or after the December 2025 Depo-Provera label change, then (c) they can file new Depo-Provera lawsuits in 2026 (or later in time) alleging failure to warn about the meningioma side effect.
This is because the new meningioma warning has to do with women being informed about the benefits and risks of a Depo-Provera injection at the time it was received. And, as stated above, before the December 2025 Depo-Provera label change, there was no meningioma warning in any of the previous Depo-Provera drug labels, also known as the Prescribing Information documents.
In summary, here are the two primary factors for whether a woman can file a Depo-Provera meningioma drug injury lawsuit against the responsible pharmaceutical drug companies:
(1) Before December 2025, the woman must have received at least 1 injection of any of the following:
- Brand name Depo‐Provera 150mg IM Injections (Upjohn, Pharmacia, Pfizer)
- Brand name Depo‐SubQ 104 Provera (Upjohn, Pharmacia, Pfizer)
- An “authorized generic” version of Depo‐Provera manufactured by Pharmacia & Upjohn Company LLC, Greenstone LLC, or Prasco Laboratories
(2) At some time after that injection, the woman received a diagnosis of some type of meningioma, such as intracranial meningioma, from a medical doctor.
We are handling these Depo-Provera meningioma drug injury lawsuits for women who want to get legal compensation from the responsible pharmaceutical companies.
We point out that these Depo-Provera lawsuits would not be filed against the doctors who prescribed the Depo-Provera injections because the failure to warn about the meningioma side effect was not disclosed until December 2025, when the Depo-Provera label change added a meningioma warning.
We have written previously over on our Drug Injury Watch website about the medical and legal aspects of Depo-Provera meningioma cases:
Meningioma Warning For Depo-Provera Recommended in Europe by Drug Regulator (February 7, 2025)
Depo-Provera Drug Label Warnings in US Do Not Include Increased Risk of Intracranial Meningioma (January 30, 2025)
Side Effects of Birth Control: Brain Tumors Related to Depo-Provera Contraceptive Injections (October 16, 2024)
If you or someone you know has a possible Depo-Provera lawsuit, we suggest submitting a Case Evaluation Form online or calling our office (910-256-2971) to discuss the case facts with drug injury attorney Tom Lamb.
[Read the article in full at Drug Injury Watch]Depo-Provera Contraceptive Injection
Free Case Evaluation
Strictly Confidential, No Obligation